SCHEMBL25834818

SCHEMBL25834818

CC(C)C(=O)CCn1cc(C(C)C)nn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.36
NTRK1 P04629 8/20 0.32
GPR88 Q9GZN0 1/20 0.32
HRH4 Q9H3N8 2/20 0.32
HRH3 Q9Y5N1 2/20 0.32
USP2 O75604 1/20 0.31
TP53 P04637 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
ALOX15 P16050 1/20 0.31
CASP3 P42574 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
SENP6 Q9GZR1 1/20 0.31
HDAC1 Q13547 3/20 0.31
HDAC3 O15379 2/20 0.31
HDAC4 P56524 2/20 0.31
HDAC7 Q8WUI4 2/20 0.31
HDAC2 Q92769 2/20 0.31
HDAC10 Q969S8 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25873267 0.88 HDAC3 (0.41) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL16171674 0.83 NTRK1 (0.38) NTRK1GPR88
SCHEMBL23330459 0.79 NR1H4 (0.38) NR1H4HRH4HRH3CYP1A2HDAC1
SCHEMBL21151016 0.79 HDAC3 (0.35) HRH4HRH3HDAC1HDAC3HDAC4
SCHEMBL26731321 0.79 NR1H4 (0.36) NR1H4HDAC1CSNK2A1DPP4
SCHEMBL17170565 0.78 GGPS1 (0.40) NR1H4HDAC1CSNK2A1DPP4
SCHEMBL19086059 0.78 NTRK1 (0.37) NTRK1GPR88HRH4HRH3CYP1A2
SCHEMBL23589770 0.77 GGPS1 (0.37) NR1H4HDAC1CSNK2A1
SCHEMBL19400545 0.75 HRH4 (0.35) HRH4HRH3
SCHEMBL13453642 0.75 SMPD1 (0.41) HRH4HRH3HDAC1HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 NR1H4 296/4885NTRK1 3174/4885GPR88 1902/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 NR1H4 2116/4885NTRK1 2305/4885GPR88 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.